|
ISIN No
|
INE312C01025
|
BSE Code / NSE Code
|
524470 / SYNCOMF
|
Book Value (Rs.)
|
4.68
|
Face Value
|
1.00
|
|
Bookclosure
|
23/09/2026
|
52Week High
|
27
|
EPS
|
0.81
|
P/E
|
27.00
|
|
Market Cap.
|
2063.30 Cr.
|
52Week Low
|
10
|
P/BV / Div Yield (%)
|
4.69 / 0.46
|
Market Lot
|
1.00
|
|
Security Type
|
Other
|
|
The company history sections lists out major chronological events that happened to the company.
| Syncom Formulations (India) Limited - a renowned name in the Indian Pharmaceutical Industry represents SYNergistic COMbination for health.
-Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur (30kms away from Indore, the commercial capital of Madhya Pradesh, India). Established in the year 1995, Syncom's state of art WHO-GMP and ISO 9001-2015 certified plant is geared up with latest production machineries and maintains high quality standards. Currently pharmaceutical formulation products SYNCOM manufactures and markets more than 500+ products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials & Ampoule Injections & Dry powder injections, Ophthalmic preparations, Dry Syrups and suspensions , Ointments, Creams, Gel , ORS & Jelly
1988
-Syncom Formulation (India) Ltd. was established.
2005
-Company had allotted 2.65lakh fully paid-up equity shares of Rs 10 each at a premium of Rs 80 per share on the preferential basis.
2006
-Board of directors of the company had considered issue of 2.95 equity shares aggregating to Rs 1.59 crore on preferential basis.
-The comapny approved an Rs 7.1 crore plan to install two wind mills of 0.60 MW each at Sangli in Maharashtra.
2008
-Board of directors of the company had approved amendment in the Articles of Association for insertion of clauses relating to authorizing the board for issuance of warrants convertible into equity shares of the company.
-On 25th March 2008, board of directors of the company had transacted the allotment of 3.1 lakh equity shares of Rs 10 each by way of preferential allotment at a premium of Rs 36per equity share to Shri. Kedarmal Bankda, promoter of the company.
-On the same date board of directors of the company had transacted the allotment of 3.25 lakh warrants of Rs 46 each.
2009
-Syncom Formulations India has recommended the dividend @ Rs. 0.50 (5%) on equity shares of Rs. 10/- each
-Syncom Formulation (India) Ltd Issues Rights in the Ratio of 1:2
2011
-Mrs. Shikha Sethi, has been appointed as the Company secretary of the Company
2012
-Company has incorporated a Wholly Owned Subsidiary Company in the name of "TRADE ZONE FZE" in the United Arab Emirates
-Shri. Praveen Jindal has been appointed as an Independent Director of the company.
2013
-The Company in the proportion of 5 (Five) Equity Shares of Rs. 1 (Rs. One) for every 2 (Two) Equity Shares of Rs. 1 (Rs. One) held by them on the record date as may be decided by the Board with the consultation of the Stock Exchange.
-The Company has recommend a dividend Rs. 0.60 (Sixty paise) (6%) per equity share of Rs. 10/- each for the year 2012-13,
-Syncom Formulation (India) has announces bonus in the ratio of 5:2
-Syncom Formulation (India) has splits its face value from Rs 10/- to 1/-
2014
-The Company has recommend a dividend of Rs. 0.02 (Two paise) (2%) per equity share of Re. 1/- each for the year 2013-14
-The Company has appointed Smt. Rinki Bankda in the category of Women Director as an Additional Director of the Company w.e.f. August 13, 2014.
2022 -Syncom Formulations (India) Limited has awarded 'PRODUCT EXCELLENCE 2022' under the category of 'Pharma (Medium)'organized.
|